BioRestorative Therapies (NASDAQ: BRTX) director Dhaliwal files clean Form 3

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. director Jatinder Dhaliwal filed an initial ownership report on Form 3. The filing lists him as a director and shows no reportable transactions or derivative positions at this time, indicating there were no recent insider trades disclosed in this report.

Key Terms

Form 3, reportingPersons, derivativeSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [{"name": "Dhaliwal Jatinder""

derivativeSummary financial

""derivativeSummary": []"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/18/2026 - 12:40 PM Accepted by SEC EDGAR 06/18/2026 - 12:39 PM Learn about SEC filing dates

FAQ

What does the BioRestorative Therapies (BRTX) Form 3 for Jatinder Dhaliwal show?

The Form 3 shows that Jatinder Dhaliwal is a director of BioRestorative Therapies. It reports no insider buy or sell transactions and no derivative holdings in this initial ownership statement.

Are there any insider share purchases or sales in the BRTX Form 3 filing?

No, the Form 3 shows zero buy and sell transactions for BioRestorative Therapies. Transaction counts and share totals in the filing are all zero, indicating no recent reportable trades.

Does the BioRestorative Therapies Form 3 disclose any options or derivative securities?

No, the derivative section of the Form 3 is empty for BioRestorative Therapies. The derivativeSummary shows no derivative positions and no exercises or conversions associated with this reporting person.

What is the role of the reporting person in the BRTX Form 3?

The reporting person, Jatinder Dhaliwal, is identified as a director of BioRestorative Therapies. The filing does not list him as an officer or ten percent owner, focusing solely on his director status.

Does the BioRestorative Therapies Form 3 indicate any gifts or tax-related share transfers?

No, the Form 3 lists zero gifts and zero tax-withholding share transfers. GiftCount, giftShares, taxWithholdingCount, and taxWithholdingShares fields are all zero for this reporting person.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dhaliwal Jatinder

(Last) (First) (Middle)

40 MARCUS DRIVE

C/O BIORESTORATIVE THERAPIES, INC.

(Street)

MELVILLE NEW YORK 11747

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/10/2026

3. Issuer Name and Ticker or Trading Symbol
BioRestorative Therapies, Inc. [ BRTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jatinder Dhaliwal	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)